相似文献
1
Pharmacologic targets and peritoneal membrane remodeling.药理靶点与腹膜重塑
Perit Dial Int. 2014 Jan-Feb;34(1):114-23. doi: 10.3747/pdi.2011.00332.
2
The dipeptide alanyl-glutamine ameliorates peritoneal fibrosis and attenuates IL-17 dependent pathways during peritoneal dialysis.二肽丙氨酰谷氨酰胺可改善腹膜纤维化，并在腹膜透析过程中减弱白细胞介素-17依赖性途径。
Kidney Int. 2016 Mar;89(3):625-35. doi: 10.1016/j.kint.2015.12.005. Epub 2016 Jan 8.
3
Peritoneal Membrane Preservation.腹膜保护
Semin Nephrol. 2017 Jan;37(1):77-92. doi: 10.1016/j.semnephrol.2016.10.009.
4
Complement system activation and peritoneal membrane alterations: Culprit or innocent bystander?补体系统激活与腹膜结构改变：罪魁祸首还是无辜旁观者？
Perit Dial Int. 2020 Mar;40(2):115-123. doi: 10.1177/0896860819896242. Epub 2020 Jan 13.
5
Mechanisms and interventions in peritoneal fibrosis.腹膜纤维化的机制与干预措施。
Clin Exp Nephrol. 2012 Feb;16(1):109-14. doi: 10.1007/s10157-011-0533-y. Epub 2011 Sep 21.
6
Strategies for preventing peritoneal fibrosis in peritoneal dialysis patients: new insights based on peritoneal inflammation and angiogenesis.预防腹膜透析患者腹膜纤维化的策略：基于腹膜炎症和血管生成的新见解。
Front Med. 2017 Sep;11(3):349-358. doi: 10.1007/s11684-017-0571-2. Epub 2017 Aug 8.
7
New developments in peritoneal fibroblast biology: implications for inflammation and fibrosis in peritoneal dialysis.腹膜成纤维细胞生物学的新进展：对腹膜透析中炎症和纤维化的影响
Biomed Res Int. 2015;2015:134708. doi: 10.1155/2015/134708. Epub 2015 Oct 1.
8
Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion.口服补充舒洛地特可抑制腹膜灌注大鼠模型中的新生血管形成。
Nephrol Dial Transplant. 2012 Feb;27(2):548-56. doi: 10.1093/ndt/gfr370. Epub 2011 Jul 12.
9
Pathophysiological Mechanisms of Peritoneal Fibrosis and Peritoneal Membrane Dysfunction in Peritoneal Dialysis.腹膜透析中腹膜纤维化和腹膜功能障碍的病理生理机制。
Int J Mol Sci. 2024 Aug 7;25(16):8607. doi: 10.3390/ijms25168607.
10
TGF-β1-VEGF-A pathway induces neoangiogenesis with peritoneal fibrosis in patients undergoing peritoneal dialysis.TGF-β1-VEGF-A 通路诱导接受腹膜透析患者的新生血管形成和腹膜纤维化。
Am J Physiol Renal Physiol. 2018 Feb 1;314(2):F167-F180. doi: 10.1152/ajprenal.00052.2017. Epub 2017 Oct 4.
引用本文的文献
1
Deletion of p38 MAPK in macrophages ameliorates peritoneal fibrosis and inflammation in peritoneal dialysis.巨噬细胞中 p38MAPK 的缺失可改善腹膜透析中的腹膜纤维化和炎症。
Sci Rep. 2024 Sep 11;14(1):21220. doi: 10.1038/s41598-024-71859-5.
2
STAT3/HIF-1α signaling activation mediates peritoneal fibrosis induced by high glucose.STAT3/HIF-1α 信号通路激活介导高糖诱导的腹膜纤维化。
J Transl Med. 2021 Jun 30;19(1):283. doi: 10.1186/s12967-021-02946-8.
3
Is there such a thing as biocompatible peritoneal dialysis fluid?是否存在生物相容的腹膜透析液？
Pediatr Nephrol. 2017 Oct;32(10):1835-1843. doi: 10.1007/s00467-016-3461-y. Epub 2016 Oct 8.
4
Inhibition of EGF Receptor Blocks the Development and Progression of Peritoneal Fibrosis.表皮生长因子受体的抑制作用可阻断腹膜纤维化的发展与进程。
J Am Soc Nephrol. 2016 Sep;27(9):2631-44. doi: 10.1681/ASN.2015030299. Epub 2015 Dec 17.
本文引用的文献
1
Changes in peritoneal membrane permeability and proteinuria in patients on peritoneal dialysis after treatment with paricalcitol − a preliminary study.帕立骨化醇治疗后腹膜透析患者腹膜通透性和蛋白尿的变化——一项初步研究
Clin Nephrol. 2012 Aug;78(2):93-9. doi: 10.5414/CN107570.
2
Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.生物相容性与标准液对腹膜透析结果的影响。
J Am Soc Nephrol. 2012 Jun;23(6):1097-107. doi: 10.1681/ASN.2011121201. Epub 2012 Mar 22.
3
Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients--a randomized crossover trial.吡格列酮治疗 12 周可显著改善持续性不卧床腹膜透析患者的代谢紊乱和减轻炎症——一项随机交叉试验。
Perit Dial Int. 2012 Sep-Oct;32(5):507-15. doi: 10.3747/pdi.2011.00116. Epub 2012 Mar 1.
4
The effect of vitamin D derivatives on vascular calcification associated with inflammation.维生素D衍生物对与炎症相关的血管钙化的影响。
Nephrol Dial Transplant. 2012 Jun;27(6):2206-12. doi: 10.1093/ndt/gfr555. Epub 2011 Oct 24.
5
Pharmacological modulation of peritoneal injury induced by dialysis fluids: is it an option?透析液诱导的腹膜损伤的药理学调节：这是一种选择吗？
Nephrol Dial Transplant. 2012 Feb;27(2):478-81. doi: 10.1093/ndt/gfr543. Epub 2011 Sep 29.
6
Angiogenesis in peritoneal dialysis.腹膜透析中的血管生成。
Kidney Blood Press Res. 2011;34(4):245-52. doi: 10.1159/000326953. Epub 2011 Jun 21.
7
L-carnitine is an osmotic agent suitable for peritoneal dialysis.左旋肉碱是一种适合腹膜透析的渗透剂。
Kidney Int. 2011 Sep;80(6):645-54. doi: 10.1038/ki.2011.117. Epub 2011 Apr 27.
8
Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis.苯磷汀可预防腹膜透析中腹膜和肾脏损伤。
J Am Soc Nephrol. 2011 May;22(5):914-26. doi: 10.1681/ASN.2010070750. Epub 2011 Apr 21.
9
Difference in the expression of hormone receptors and fibrotic markers in the human peritoneum--implications for therapeutic targets to prevent encapsulating peritoneal sclerosis.人类腹膜中激素受体和纤维生成标志物表达的差异——预防包裹性腹膜硬化症治疗靶点的启示。
Perit Dial Int. 2011 May-Jun;31(3):291-300. doi: 10.3747/pdi.2010.00118. Epub 2011 Mar 31.
10
The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both?中性 pH 值、低 GDP 腹膜透析液的生物相容性：是仅在实验室有益，还是在病床和实验室均有益？
Kidney Int. 2011 Apr;79(8):814-24. doi: 10.1038/ki.2010.515. Epub 2011 Jan 19.
Zotero 插件